Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

12.10 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 12.10
Bid (Size) 10.00 (20)
Ask (Size) 19.35 (1)
Prev. Close 12.10
Today's Range 12.10 - 12.10
52wk Range 8.900 - 18.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech Reports Financial Results for the First Nine Months of 2024
From Alvotech
Via GlobeNewswire
Earnings Scheduled For November 13, 2024
Via Benzinga

Performance

YTD
+6.51%
+6.51%
1 Month
-1.22%
-1.22%
3 Month
-6.85%
-6.85%
6 Month
-10.37%
-10.37%
1 Year
+32.39%
+32.39%

More News

Read More
Alvotech's Earnings Outlook
Via Benzinga
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
ALVO Stock Earnings: Alvotech Misses Revenue for Q2 2024
Via InvestorPlace
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Alvotech
Via GlobeNewswire
Vipshop, Hesai Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
From Alvotech
Via GlobeNewswire
Alvotech Announces Closing of Private Debt Financing
From Alvotech
Via GlobeNewswire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Issues New Shares to Holders of Convertible Bonds
From Alvotech
Via GlobeNewswire
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
From Alvotech
Via GlobeNewswire
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
From Alvotech
Via GlobeNewswire
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
From Alvotech
Via GlobeNewswire
Alvotech and STADA add to strategic alliance through denosumab partnership
From Alvotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.